Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765921 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
A Phase 1 study of Choroidal Melanoma, sponsored by Massachusetts Eye and Ear Infirmary.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00765921 is a Phase 1 study of Choroidal Melanoma that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 40 participants, below the 203-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00765921, a Phase 1 study of Choroidal Melanoma, has completed, sponsored by Massachusetts Eye and Ear Infirmary.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to investigate the safety and tolerability of the anti-VEGF (vascular endothelial cell growth factor) treatment, ranibizumab, in combination with proton beam irradiation for the treatment of choroidal melanoma by determining the incidence and severity of ocular adverse events. Systemic adverse events will also be evaluated. A secondary objective is to assess the efficacy of ranibizumab in reducing ocular complications that can occur after irradiation.
Conditions Studied
Interventions
- DRUG ranibizumab
Study Locations (1)
Massachusetts
- Massachusetts Eye & Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765921
The ClinicalTrials.gov registry entry for NCT00765921 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (80% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Choroidal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which ranibizumab is the first listed.
NCT00765921 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00765921 about?
NCT00765921 is a clinical study titled "Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma". The purpose of the study is to investigate the safety and tolerability of the anti-VEGF (vascular endothelial cell growth factor) treatment, ranibizumab, in combination with proton beam irradiation for the treatment of choroidal melanoma by determining the incidence and severity of ocular adverse ev...
What is the current status of trial NCT00765921?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-06. Estimated completion is 2016-09.
What conditions does trial NCT00765921 study?
This clinical trial studies the following conditions: Choroidal Melanoma.
What interventions are being tested in trial NCT00765921?
The interventions under investigation include: ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00765921?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00765921 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroidal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
RECRUITING
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.